contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


biogaia-appoints-theresa-agnew-as-new-ceo

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

BioGaia är ett bioteknikbolag verksamt inom läkemedelsbranschen och fokuserar på utveckling, tillverkning och distribution av probiotika för hälsa och välbefinnande. Bolagets produkter riktar sig till privatpersoner och sjukvårdsinstitutioner. Verksamheten är global med en huvudsaklig närvaro i Europa, Nordamerika och Asien. BioGaia grundades 1990 och har sitt huvudkontor i Stockholm.

BioGaia

Today BioGaia's board of directors has appointed Theresa P. Agnew as the new chief executive officer.Theresa Agnew is a global business leader with consumer healthcare, OTC, and medical device...

<div class="abstract">Today BioGaia's board of directors has appointed Theresa P. Agnew as the new chief executive officer.</div>Theresa Agnew is a global business leader with consumer healthcare, OTC, and medical device experience from leading companies such as GlaxoSmithKline (GSK), Essilor and Johnson &amp; Johnson. She has extensive experience after more than 20 years in leadership roles, managing teams of more than 500 employees. She brings solid international experience having lived and worked in Europe, the US and Australia and the Far East. She has a deep understanding of, and success, in the international healthcare market(s). Theresa holds a B.S. in Biology from Boston College.At GSK she led their OTC global business across multiple segments of Pain Relief, Respiratory Health and Skin Health in OTC pharmaceuticals, naturals, supplements and medical devices in the largest OTC company worldwide.Currently, Theresa Agnew is working at a diabetes start-up, preparing for commercial launch and structuring the company to scale."We are extremely pleased that we have been able to recruit Theresa Agnew", says BioGaia's founder and chair Peter Rothschild, and he continues: "She has successfully led OTC, diagnostics, and consumer health brands with a strong scientific basis and been a pioneer expanding distribution through internet platforms. She brings experience from turnaround environments as well as growth-oriented roles. Theresa has a deep knowledge of life science, as well as how to build and market strong and relevant consumer brands. Theresa will drive BioGaia to further accelerate its profitable growth journey and potential.""I am very excited about this opportunity and really look forward to contributing to an already successful business model and working with the talented global BioGaia team to grow BioGaia and create value for our consumers and shareholders", says Theresa Agnew, future CEO of BioGaia.Theresa Agnew will join the company subject to the successful completion of the pending work permit application process, with an expected starting date as of September 25, or such later date as may be necessary to comply with these requirements. &nbsp;Follow us: Subscribe to BioGaia press releases&nbsp;here&nbsp;(<a href="https://www.biogaia.com/press/subscribe-to-press-releases/">https://www.biogaia.com/press/subscribe-to-press-releases/</a>) LinkedIn here&nbsp;(<a href="https://www.linkedin.com/company/biogaia-ab/">https://www.linkedin.com/company/biogaia-ab/</a>) Contacts: Peter Rothschild, Chairman of the Board Email: pr@biogaia.se Phone: +46 708 30 65 40About BioGaia BioGaia is an innovative Swedish healthcare company that develops, markets, and sells probiotic products with documented health benefits. The products are sold through local distribution partners or via own distribution in over 100 markets. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaia.com&nbsp;(<a href="https://www.biogaia.com/">https://www.biogaia.com/</a>)This disclosure contains information that BioGaia is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person set out above, at 3:30 p.m. CEST on August 2, 2023.